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The efficacy of B cell depletion therapies in diseases such as nephrotic syndrome and rheumatoid
arthritis suggests a broader role in B cells in human disease than previously recognized. In some of
these diseases, such as the minimal change disease subtype of nephrotic syndrome, pathogenic
antibodies and immune complexes are not involved. We hypothesized that B cells, activated in
the kidney, might produce cytokines capable of directly inducing cell injury and proteinuria. To
directly test our hypothesis, we targeted a model antigen to the kidney glomerulus and showed that
transfer of antigen-specific B cells could induce glomerular injury and proteinuria. This effect was
mediated by IL-4, as transfer of IL-4–deficient B cells did not induce proteinuria. Overexpression
of IL-4 in mice was sufficient to induce kidney injury and proteinuria and could be attenuated by
JAK kinase inhibitors. Since IL-4 is a specific activator of STAT6, we analyzed kidney biopsies and
demonstrated STAT6 activation in up to 1 of 3 of minimal change disease patients, suggesting IL-4
or IL-13 exposure in these patients. These data suggest that the role of B cells in nephrotic syndrome
could be mediated by cytokines.
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B cell depletion therapies (BCDTs), such as rituximab, are efficacious in numerous immune-mediated diseases, including rheumatoid arthritis and multiple sclerosis (1). Current BCDTs target CD20 and eliminate
B cells but not antibody-producing plasma cells because they do not express CD20 (2). Indeed, most autoantibodies remain present after depletion despite clinical response (3), suggesting that B cells may contribute to tissue injury in an antibody-independent manner.
Since the first reports in 2004 of the successful treatment of steroid-sensitive nephrotic syndromes
(SSNS), such as minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), using
rituximab (4–6), there are now over 200 publications in the literature. The majority of these are anecdotal
reports and small uncontrolled studies, but the consensus today is that BCDTs are likely efficacious for steroid-sensitive, relapsing forms of disease. By definition, autoreactive antibodies and immune complexes are
absent in MCD and FSGS (7). Current therapies are based on the idea that immune dysfunction, potentially involving T cells, is involved in the pathogenesis of these diseases, as first proposed by Shalhoub (8). This
idea is supported by the responsiveness of most MCD/FSGS patients to immunosuppressive therapies.
Furthermore, the clinical observation that some patients with nephrotic syndrome respond to plasmapheresis suggests that a soluble, circulating factor may be responsible (9, 10). The efficacy of BCDTs supports
an immune origin of disease for some nephrotic patients. However, a specific mechanism to explain disease
pathogenesis is still lacking.
Given the absence of pathogenic antibodies in these diseases, a role for B cells would need to be
antibody independent. In recent years, antibody-independent functions have been ascribed to B cells.
Mouse models of systemic lupus erythematosus (SLE) demonstrate that B cells are as important as
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Figure 1. Rituximab does not bind SMPDL3B in nonfixed samples. (A) Western blot of transfected 293T and Raji cells. Whole-cell lysates were subjected
to SDS-PAGE, followed by immunoblotting with antibodies as indicated. β-Actin was used as loading control. (B) Rituximab does not bind to SMPDL3B
in nonfixed cells. Nonfixed or PFA-fixed 293T cells expressing HA-SMPDL3B were stained with α-HA-AF488 and rituximab-AF647 and analyzed by flow
cytometry. Data are representative of 3 independent experiments.

antigen-presenting cells for autoreactive T cells (11). B cells can also make cytokines that can either promote or inhibit inflammation (12, 13). Cytokines produced by B cells are required for the development
of lymph node and ectopic lymphoid follicles, can amplify T cell responses, and can suppress arthritis,
colitis, and experimental autoimmune encephalitis in mice (14, 15).
The cardinal pathologic feature of nephrotic diseases is foot process effacement of the glomerular
podocyte. The glomerulus houses the glomerular filtration barrier, where a highly differentiated epithelial cell known as the podocyte forms the final cellular barrier for the filtration of blood and generation
of urine. Podocytes have a specialized architecture characterized by interdigitating cellular arborizations
(foot processes) that form a mesh-like structure on the urinary aspect of the glomerular capillaries. In all
cases of active proteinuria, podocytes exhibit a simplification and flattening/retraction of the podocyte foot
processes, a finding termed foot process effacement. Given the lack of cellular inflammation or immune
complexes in MCD and FSGS, the likeliest scenario for an immunologic cause would be a factor secreted
by an immune cell.
In this study, we directly tested whether cytokines produced by B cells could induce podocyte foot process effacement and proteinuria. Using an in vitro assay of podocyte injury, we identified IL-4 as a cytokine
capable of stimulating membrane ruffling of podocytes and detachment of podocytes from the basement
membrane in vitro. Using a method of in vivo gene delivery, we confirmed that IL-4 is sufficient to induce
foot process effacement and proteinuria when overexpressed in mice. To determine whether B cells activated locally in the kidney could make enough IL-4 to induce foot process effacement, we planted a B cell
antigen on the glomerular basement membrane (GBM) and showed that antigen-specific B cells could
induce foot process effacement in an IL-4–dependent fashion. Finally, we found evidence of IL-4 receptor
signaling in the kidneys in some patients with MCD. Taken together, these findings reveal a mechanism for
the efficacy of anti–B cell therapies in the treatment of steroid-sensitive nephrotic diseases. These results
also suggest that IL-4 is a potential nephrotic factor and therapeutic target.

Results
Rituximab does not bind SMPDL3B in nonfixed cells. It was recently proposed that the effect of rituximab on
nephrotic syndrome is not due to B cells but is instead mediated by its off-target binding to sphingomyelin-phosphodiesterase-acid-like-3b (SMPDL3B) expressed on podocytes (16). To confirm the binding of SMPDL3B by
rituximab, we overexpressed HA-tagged SMPDL3B in 293T cells that do not endogenously express either
CD20 or SMPDL3B. Expression and membrane localization of HA-SMPDL3B were confirmed by immunoblotting and immunofluorescence with HA and SMPDL3B antibodies (Figure 1A and Supplemental Figure 1,
A and B; see complete unedited blots in the supplemental material; supplemental material available online with
this article; https://doi.org/10.1172/jci.insight.81836DS1). Modeling suggested that the N-terminal HA-tag
is spatially separated from the SMPDL3B epitope (156ELWKPW161) reported to be recognized by rituximab
(Supplemental Figure 1C).
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Figure 2. IL-4 induces podocyte membrane ruffling and widespread foot process retraction. (A) Differential interference contrast live-cell imaging was
used to obtain kymographs from individual differentiated cultured murine podocytes. Each cell was imaged individually from separate podocyte cultures.
Representative kymographs (time = 20 minutes) before (left column) and after (right column) the addition of IL-4 (10 ng/ml, top row) or IL-4 with anti–IL-4
antibody (5 μg/ml, bottom row) are shown. IL-4 caused pronounced membrane ruffling that was abrogated by anti–IL-4 treatment (also see Supplemental Videos 1 and 2). Original magnification, ×~1,100. (B) Kymograph analysis was used to quantitate actin spike lengths (ruffling index) of 5 locations per
cultured podocyte for the cytokines tested (IL-13: 10 ng/ml, IFN-γ: 100 ng/ml, TNF-α: 10 ng/ml). IL-4 and IL-13 have enhanced membrane ruffling dynamics. IL-4 promoted an equivalent level of ruffling as a known activator of Rac, EGF (20 ng/ml), which was reversed with anti–IL-4 antibody. Each symbol
represents the average relative cell membrane displacement over time at 5 regions of a single cell. Each cell mean ± SD of 3 experiments, with 3–4 cells/
experiment (total of 10 cells analyzed/group). (C) Representative scanning electron microscopy images of glomeruli from minced renal cortices incubated
ex vivo for 20 minutes with IL-4 (10 ng/ml), IL-4 with anti–IL-4 antibody (5 μg/ml), TNF-α (10 ng/ml), or positive control EGF (20 ng/ml). IL-4 treatment
induced massive foot process retractions similar to that induced by EGF. TNF-α and IL-4 plus anti–IL-4 did not alter foot process morphology, consistent
with the membrane ruffling data. Scale bar: 20 μm. *P < 0.001, **P < 0.005, ***P < 0.004, ****P < 0.03 by 1-way ANOVA with Bonferroni correction.

To mimic the in vivo setting, we incubated nonfixed cells with rituximab and an anti-HA tag antibody.
In 293T cells expressing HA-SMPDL3B, staining was detected with an anti-HA antibody but not with rituximab (Figure 1B and Supplemental Figure 2, A and B). Notably, when cells were fixed with paraformaldehyde (PFA) prior to antibody staining, we observed marked binding of rituximab to cells, regardless of
SMPDL3B expression (Figure 1B and Supplemental Figure 2, A and B). Similar results were obtained with
HeLa cells overexpressing HA-SMPDL3B (Supplemental Figure 3, A and B; see complete unedited blots in
the supplemental material). Binding of rituximab to CD20 was confirmed by staining Raji cells (Supplemental Figure 1D). These results suggest that rituximab does not bind to SMPDL3B in vivo and that the binding
previously reported is not specific. This suggests that the efficacy of rituximab in nephrotic kidney diseases
is not through its ability to bind and directly modulate podocytes. We therefore considered antibody-independent B cell functions.
IL-4 and IL-13 induced membrane ruffling in cultured podocytes and foot process retraction in kidney fragments in vitro.
B cells secrete a diverse array of cytokines upon activation, including IFN-γ, TNF-α, IL-4, and IL-13 (13, 17–
20). Conversely, podocytes express cytokine receptors, including receptors for IFN-γ, TNF-α, IL-4, and IL-13
(21–23). Therefore, we tested individual cytokines for their ability to induce foot process effacement in vitro.
insight.jci.org   https://doi.org/10.1172/jci.insight.81836
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Figure 3. Mice treated with a plasmid encoding IL-4
exhibited proteinuria, foot process abnormalities,
and STAT6 activation in glomeruli. (A) 129X1/SvJ
mice were hydrodynamically injected with either
IL-4 piggyBac plus transposase vectors to induce
IL-4 expression (IL-4 treated) or empty piggyBac
plus transposase vectors (control). Representative Coomassie blue–stained SDS-PAGE. (B) Spot
albumin/creatinine ratios of urine from control or
IL-4–treated mice demonstrated proteinuria with IL-4
expression. Urine was collected 12 hours after plasmid
injection. (C) Serum IL-4 ELISA confirmed elevated
expression of IL-4 in IL-4 gene–treated mice. Symbols
represent individual mice, and bars represent the
geographic mean in B and mean in C. Mean ± SD of 3
experiments, with total of 5 mice/group. *P < 0.006,
**P < 0.001 by 2-tailed Mann-Whitney. (D) Representative scanning electron microscopy (scale bar: 1
μm) revealed foot process retraction with focal foot
process effacement in IL-4–treated mice compared
with control. (E) Representative immunohistochemical analysis of glomerular pSTAT6 expression reveals
substantial STAT6 phosphorylation and nuclear translocation in IL-4–treated mice (black arrows) compared
with control. Original magnification, ×400. Data are
representative of 4 independent experiments.

We have proposed that the activation of the small GTPase Rac is the cell biological correlate for foot process
effacement in vivo (24, 25). Rac is a member of the Rho family of small G proteins, which also includes Cdc42
and Rho. Rac activation stimulates the formation of actin cytoskeletal structures that are associated with cell
migration and membrane ruffling (26). Rac activation in podocytes acutely induces foot process effacement
and proteinuria in mice (24, 25).
Cytokines were added to cultured murine podocytes, and differential interference contrast live-cell
imaging of individual cells in separate culture dishes was used to evaluate the response. Membrane ruffling
was used as a surrogate for Rac activation, and kymograph analysis was used to quantitate membrane
ruffling before and after addition of the cytokine (25, 27). IL-4 and, to a lesser extent, IL-13 induced membrane ruffling, while TNF-α and IFN-γ had no effect on membrane ruffling (Figure 2, A and B, and Supplemental Videos 1 and 2). IL-4 stimulated a similar degree of ruffling as EGF, a known activator of Rac
(28). The addition of a neutralizing IL-4 antibody abrogated IL-4–induced membrane ruffling (Figure 2B),
indicating that the effect was IL-4 specific.
Since cultured podocytes do not form foot processes, we minced murine renal cortices where the glomeruli
are located and treated these fragments with cytokines to evaluate for abnormalities in foot process morphology. Using scanning electron microscopy, we found that IL-4 induced severe foot process retractions, podocyte
detachment, and exposure of the glomerular capillary wall, while TNF-α did not (Figure 2C). The changes
induced by IL-4 were comparable to those induced by EGF and were blocked with anti–IL-4 antibody (Figure
2C). These data confirmed the ability of IL-4 to directly induce podocyte damage in ex vivo renal cortex.
insight.jci.org   https://doi.org/10.1172/jci.insight.81836
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Figure 4. Inhibition of IL-4 signaling with JAK1/3 inhibitor abrogated ruffling and proteinuria in IL-4–treated mice. (A) Representative kymographs
obtained by membrane ruffling and (B) quantification, as performed in Figure 1, from cultured podocytes treated with the JAK1/3 inhibitor tofacitinib (100
nM, bottom row), which significantly attenuated IL-4–induced membrane ruffling compared with negative control (DMSO). Each symbol represents the
average relative cell membrane displacement over time at 5 regions of a single cell. Mean ± SD of 2 experiments, with 2–3 cells/experiment (total of 5 cells
analyzed/group). (C) Coomassie blue–stained SDS-PAGE and (D) spot albumin/creatinine ratios of urine from IL-4–treated mice treated with JAK1/3 inhibition, which significantly reduced IL-4–induced proteinuria. Urine was collected 24 hours after plasmid administration. Symbols represent individual mice,
and bars represent the mean. Mean ± SEM of 2 experiments, with total of 5 mice/group. *P < 0.008 by 2-tailed Mann-Whitney.

IL-4 overexpression induces proteinuria and IL-4 signaling in the glomerulus in vivo, which is reduced with JAK1/3
inhibition. To evaluate the role of IL-4 in vivo, we expressed IL-4 in mice by injecting a plasmid based on a
transposon expression system using hydrodynamic injection (29–31). In this system, the gene of interest integrates into the genome in a site-specific fashion, primarily in hepatocytes, allowing for efficient and high-level expression of the introduced gene (32). Delivery of the IL-4 gene induced marked proteinuria (Figure 3,
A and B; see complete unedited blots in the supplemental material) with a severity that directly correlated with
serum levels of IL-4 (Figure 3C). No proteinuria was seen when a control targeting vector was administered.
Scanning electron microscopy performed on kidneys 3 days after plasmid administration demonstrated
blunted foot processes with scattered areas of effacement (Figure 3D). In comparison, the foot processes of
podocytes from control mice were normal. These data show that high serum levels of IL-4 via its overexpression in the liver can directly induce podocyte foot process abnormalities and proteinuria in vivo.
IL-4 signals through the IL-4 receptor (IL-4Rα and common-γ chain) to activate the tyrosine kinases
JAK1 and JAK3 and subsequently the transcription factor STAT6 (33). Kidney sections obtained from
mice 24 hours following mock or IL-4 plasmid administration were stained for 6 (pSTAT6) using immunohistochemistry (Figure 3E). IL-4 treatment strongly induced pSTAT6 within podocytes and other glomerular cells, with little to no staining detected in the glomeruli of control mice. Based on the activation of
STAT6, this supports the idea that podocytes can respond to IL-4 in vivo.
Since IL-4 utilizes the JAK1 and JAK3 kinases for signaling, we tested if JAK1/3 inhibition could
block IL-4–induced membrane ruffling in podocytes in vitro and the development of proteinuria in vivo.
A small-molecule inhibitor of JAK1 and JAK3, tofacitinib, is approved for the treatment of rheumatoid arthritis (34). Pretreatment of cultured podocytes with the inhibitor significantly decreased membrane ruffling induced by IL-4 (Figure 4, A and B). To assess its effects in vivo, mice were treated with
the inhibitor twice daily, starting 1 day prior to IL-4 gene delivery. Treatment with the JAK inhibitor
insight.jci.org   https://doi.org/10.1172/jci.insight.81836
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Figure 5. Multimerized hen egg lysozyme embedded within the glomerular basement membrane following i.v. injection. (A) The production of multimerized hen egg lysozyme (HEL). Monomeric HEL was biotinylated and then complexed with avidin to form multimers. (B) Representative Coomassie blue–
stained SDS-PAGE of monomeric and multimerized HEL demonstrated multimerized complexes of at least 120 kDa were formed. (C) Immunofluorescence
microscopy images (green = HEL complex, blue = DAPI) of frozen sections from kidneys of mice injected with multimerized HEL (left: 30 minutes after
injection, center: 7 days after injection) or monomeric HEL (right: 30 minutes after injection) and stained with anti-HEL antibody. Monomeric HEL was not
visible in glomeruli, while multimerized HEL was found in the glomeruli up to 7 days after injection. Glomeruli are outlined in circles. Original magnification, ×20. Data are representative of 3 independent experiments.

significantly attenuated the proteinuria induced by IL-4 (Figure 4, C and D; see complete unedited blots in
the supplemental material). Thus, JAK1/3 inhibition can block the effects of IL-4 on foot process effacement and proteinuria.
Generation of a B cell–dependent in vivo model of proteinuria. We next wondered if B cells could be activated in the glomerulus and whether they could produce sufficient IL-4 to induce podocyte foot process
effacement and proteinuria in vivo. To test this hypothesis, we targeted a B cell antigen to the glomerular
capillary wall, followed by an infusion of antigen-specific B cells. We chose the soluble antigen hen egg
lysozyme (HEL), as a B cell receptor–specific transgenic mouse exists for it (35). HEL has a high negative
log dissociation constant (pKi) (~12) that allows it to enter the negatively charged glomerular filtration
barrier, but its small size (14 kDa) allowed it to be freely filtered through the GBM. To trap HEL within the
glomerular capillary wall, we conjugated it to biotin, allowing us to produce larger tetrameric aggregates
using avidin (Figure 5A). The HEL multimers had a molecular weight greater than 120 kDa (Figure 5B;
see complete unedited blots in the supplemental material), well above the size exclusion limit (~60–70 kDa)
of the glomerular filtration barrier. I.v. injection of avidin/biotin/HEL complexes resulted in trapping of
multimers in the GBM within 30 minutes (Figure 5C) and was stable up to a week after injection. HEL
multimers were also detected in the liver and spleen (data not shown).
We next tested whether adoptive transfer of polarized antigen-specific B cells could induce proteinuria. B cells were polarized into B effector 2 (Be2) cells by activating them in the presence of Th2-polarized cells (Figure 6A); then they were injected into mice i.v. (13, 36). Within 24 hours, mice became
proteinuric, as detected qualitatively using SDS-PAGE of urine samples or quantitatively using a urinary albumin ELISA (Figure 6, B and C; see complete unedited blots in the supplemental material).
The proteinuria was transient, peaking between 12 and 24 hours, and specific to IL-4, since transfer of
antigen-specific B cells that were IL-4 deficient (IL-4–/–) did not induce proteinuria. IL-4–/– Be2 cells
were only deficient in IL-4, and the other cytokines produced were made at the same levels as wildtype B cells (Supplemental Figure 4). Circulating IL-4 was undetectable by ELISA in the mice injected
with antigen-specific B cells, suggesting that the effect was due to local B cell activation and release
of IL-4 (data not shown). This was supported by 2-photon imaging of B cells in the kidney (37).
insight.jci.org   https://doi.org/10.1172/jci.insight.81836
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Figure 6. HEL-specific IL-4–secreting B cells generated proteinuria in mice treated with multimerized HEL. (A) HEL-specific B cells were either polarized
in vitro into B effector 2 (Be2) cells to produce IL-4, or left unpolarized, and then stimulated through the B cell receptor with anti-μ antibody overnight. Only
Be2-polarized B cells secreted IL-4 into the supernatant, as measured by ELISA. (B) Coomassie blue–stained SDS-PAGE and (C) spot albumin/creatinine ratios
of urine from mice treated with multimerized HEL, followed by transfer of either Be2-polarized HEL-specific B cells or IL-4–deficient, Be2-polarized HEL-specific B cells. Proteinuria was observed only when B cells were capable of producing IL-4. Urine was collected 24 hours after B cell transfer. Symbols represent
individual mice, and bars represent the mean. (D) Representative still images obtained from intravital 2-photon microscopy movies (Supplemental Videos 3
and 4) of mice injected with PBS (top) or multimerized HEL (bottom), followed by the transfer of fluorescently labeled HEL-specific B cells. When glomerular
HEL was present, HEL-specific B cells arrested within glomeruli. In the absence of HEL, B cell trafficking through glomeruli was not changed. Quantum dots
were injected i.v. to identify glomeruli and vessels. Glomeruli are outlined in circles. Red: glomeruli and vessels; blue: renal tubules; yellow: HEL-specific B cells.
Original magnification, ×20. Mean ± SD of 2 experiments, with a total of 5 mice/group. *P < 0.001, **P < 0.008 by 2-tailed Mann-Whitney.

After injection of antigen, mice were anesthetized and a kidney was exteriorized. Injection (i.v.) of fluorescent dextran labeled blood vessels and allowed us to identify glomeruli. In the absence of cognate
antigen, labeled HEL-specific B cells trafficked rapidly through the glomerular capillaries. In contrast,
when antigen was present, B cells entered the glomerular capillaries and arrested their movement
within the glomeruli (Figure 6D and Supplemental Videos 3 and 4). B cell arrest within the glomerular
capillaries when antigen was present suggests that in situ recognition of antigen leads to B cell activation and cytokine secretion.
Since the activation of B cells within glomeruli could induce inflammatory changes, we performed
light and immunofluorescence microscopy to assess for pathologic changes. We observed no obvious
morphologic alterations in the glomeruli of proteinuric mice by light microscopy at all time points tested
insight.jci.org   https://doi.org/10.1172/jci.insight.81836
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Figure 7. B cell–induced proteinuria generated
foot process effacement. (A) Representative
light microscopy of H&E-stained kidney sections
from mice with B cell–induced proteinuria
revealed no pathologic changes. Original magnification, ×40. (B) Representative immunofluorescence microscopy images of kidneys from
mice with B cell–induced proteinuria (left) did
not demonstrate immunoglobulin or complement component C3 in glomeruli compared to
positive control nephrotoxic serum (right). (C)
Representative scanning electron microscopy
from kidneys showed focal foot process effacement in mice with B cell–induced proteinuria
(right) compared with control mice (left). Scale
bar: 10 μm. Data are representative of 3 independent experiments.

(Figure 7A). In addition, immunofluorescence staining of sections from proteinuric
mice showed no detectable immunoglobulin or complement deposition in glomeruli
(Figure 7B). Ultrastructural analysis of the
glomeruli using scanning electron microscopy confirmed the presence of focal foot process effacement in proteinuric mice, while
nonproteinuric control mice had normal
foot processes (Figure 7C). Thus, B cells,
activated in the kidney, can induce proteinuria and foot process effacement independent of antibodies and immune complexes.
Glomerular STAT6 activation occurs in a
subset of MCD patients. STAT6 phosphorylation is specific for signaling by IL-4 and
IL-13. To test if pSTAT6 can be detected
in humans with nephrotic syndrome, we
stained kidney biopsy sections from patients
with MCD for STAT6 activation. Since
most patients with MCD respond to initial
treatment with glucocorticoids, patients are
often biopsied only after treatment failure,
limiting the availability of naive biopsy tissue. Such patients are also by definition steroid resistant and not likely to be sensitive to
BCDTs. Twenty-nine patients with MCD, in
which a biopsy was obtained before initiation of treatment, were identified from the
Renal Pathology Services at Washington
University School of Medicine, the University of Michigan, and King’s College/Evelina Children’s Hospital (Supplemental Table 1). For controls,
we stained 23 kidney biopsies obtained for conditions unrelated to nephrotic syndrome (see Methods
for diagnoses). Two of the twenty-nine MCD biopsies demonstrated strong glomerular pSTAT6 staining, and eight had weakly positive staining (see Methods for definitions). Of 23 controls, only one
showed weakly positive pSTAT6 staining (Figure 8). While this is a small sample, these data support the
hypothesis that IL-4 and/or IL-13 may be involved in some patients with MCD.

insight.jci.org   https://doi.org/10.1172/jci.insight.81836
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Figure 8. A subset of minimal change disease patients has activated glomerular STAT6. Representative immunohistochemistry of glomerular pSTAT6
expression in selected MCD patients (described in Supplemental Table 1) and a control. Ten of twenty-nine MCD patients screened demonstrated pSTAT6
staining (untreated MCD, arrows point to stained nuclei). Twenty-two of twenty-three healthy controls had no detectable pSTAT6 staining. Of 29 MCD
patient samples stained for pSTAT6, 2 were strongly positive, 8 were weakly positive, and 19 were negative; of 22 controls samples stained for pSTAT6, 1
was weakly positive and 22 were negative (P = 0.019). Original magnification, ×400.I

Discussion
Since the first reports of rituximab in the treatment of nephrotic diseases in 2004, its use has become
an important part of the treatment armamentarium, especially for steroid-sensitive and relapsing
forms of MCD and FSGS. Since there is no known role for B cells in these diseases, how and why
rituximab mediates its efficacy is a mystery. One potential explanation is the ability of rituximab to
directly bind to SMPDL3B on the podocyte (16), reversing changes in integrin affinity. Reports that
ofatumumab, a CD20 antibody that binds to an epitope distinct from rituximab (38, 39), is also efficacious in patients with steroid-resistant FSGS (6) motivated us to reexamine this question. SMPDL3B,
a protein expressed on podocytes but also broadly expressed on monocytes and gut epithelia, was initially proposed to bind to rituximab, as it contains a peptide sequence, in the reverse orientation, to an
epitope identified in a screen for rituximab-binding sequences (40). Previous binding assays used fixed
samples and amplification steps to visualize staining of podocytes with rituximab, indicating that the
binding is weak (16). Our data suggest that the binding is not specific, suggesting that B cell depletion
is the mechanism of action.
insight.jci.org   https://doi.org/10.1172/jci.insight.81836
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Nephrotic diseases, such as MCD and FSGS, are by definition not caused by autoantibodies or by
immune complexes. A major diagnostic feature for both MCD and FSGS is foot process effacement. The
responsiveness of these diseases to immunosuppressive treatments such as glucocorticoids, calcineurin
inhibitors, and mycophenolate has led many to consider these T cell–mediated diseases, even without specific evidence. The efficacy of BCDTs in the treatment of some fraction of cases, however, supports an
immune component to these diseases.
In recent years, antibody-independent roles for B cells have emerged as important in several disease
models. B cells express MHC class II and are excellent antigen-presenting cells. In mouse models of SLE,
depletion of B cells impairs the activation of autoreactive T cells, suggesting that B cells play important
roles as antigen-presenting cells (11). Recently, there has been a growing appreciation for the regulatory
effects of B cell–derived cytokines, such as IL-10 and IL-35, on attenuating organ-specific autoimmunity in
experimental autoimmune encephalitis (14, 15). B cells can also make a wide array of both Th1 and Th2
cytokines both in vitro (41–45) and in vivo (12, 13).
We and others have suggested that an imbalance between the Rac and Rho G proteins underlies the
process of foot process effacement (24, 25, 46). Rho functions to maintain large actin structures important
for cell adhesion, while Rac functions to stimulate cell migration and membrane ruffling and spreading
(25, 26). During injury, Rac becomes active and induces the process of foot process effacement (24). Using
this knowledge, we used markers of Rac activation, such as membrane ruffling in cultured podocytes, as a
surrogate for foot process effacement. We confirmed the effects of IL-4 on podocytes in situ assay using an
assay that we developed using minced renal cortices treated ex vivo with cytokines. Our success using these
assays to identify IL-4 suggests that this assay could also be used to screen for the elusive soluble factors that
have been speculated to cause nephrotic syndrome (47).
A pathogenic role for cytokine signaling in proteinuric diseases is supported by a recent publication
describing a transgenic mouse overexpressing JAK2 in podocytes (48). When crossed with the Akita diabetic nephropathy mouse model infused with angiotensin II, enhanced proteinuria was observed that was
largely reversed with JAK2 inhibition. As JAK2 is regulated by cytokines, these data help to link cytokines
with foot process effacement.
The role of IL-4 in other glomerular injury models is controversial. It is implicated in the development of proteinuria in models of graft-versus-host disease (49–51), some models of SLE (52, 53), and IgA
nephropathy (54–58) but attenuates proteinuria induced by autologous models of nephrotoxic nephritis
(59–63). Given that autologous nephrotoxic nephritis relies on immunization against sheep antibody and
that IL-4 has direct effects on antibody isotype switching, the role of IL-4 in nephrotoxic nephritis is complex and not solely dependent on its effect on podocytes.
We are not the first to propose a role of IL-4 and IL-13 in nephrotic syndrome. IL-4 is secreted by Th2
helper T cells and associated with atopy, a condition that is highly associated with MCD (64, 65). Transgenic mice expressing IL-4 develop glomerulosclerosis (53, 66–68) and transgenic rats expressing IL-13
develop proteinuria (69). While it was reported previously that podocytes express the IL-4 receptor (IL-4Rα
and common γ-chain) and can respond to IL-4 (23), attempts to link IL-4 levels in serum and urine with
nephrotic diseases have been largely unrevealing (70, 71). One possibility is that IL-4 is produced locally at
levels too low to be detected in blood or urine.
To test whether this was a viable hypothesis, we generated a model that would allow for B cell
activation in the glomerulus. This suggested that activated B cells could produce enough IL-4 to induce
proteinuria. Notably, we were unable to detect IL-4 in the serum, showing that local IL-4 can be pathogenic. While this may not be the mechanism of disease in humans, it does suggest other potential mechanisms. Recent data show that memory lymphocytes can exist as long-term residents of tissues such
as lung and skin and far outnumber the number of lymphocytes circulating in the peripheral immune
system (72). These cells often function as cytokine-secreting sentinel cells that respond to pathogens
and/or antigens that transit through organs. Little is known yet about memory lymphocytes or innate
lymphocytes in kidney, but these specialized cells could be relevant. Finally, polyclonal B cell activators,
such as TLR ligands, released during infections and trapped by the glomerulus, could be another potent
stimulus of B cell activation (73).
We noted that IL-13 was able to induce some level of membrane ruffling in our in vitro assay. While
this is consistent with a previous study in rats showing that IL-13 can induce proteinuria, IL-13 plasmid
administration in mice did not induce proteinuria (data not shown). The reason for the difference between
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mice and rats remains unknown but may represent species-specific requirements for cytokine-induced proteinuria. Furthermore, the role of IL-13 in SSNS patients remains unclear (74), as glucocorticoid treatment
increases serum IL-13 (75).
We directly assessed for IL-4 signaling in kidney biopsies from MCD patients. Biopsies from untreated
MCD patients are difficult to procure, as patients are often initially treated without biopsy, particularly
in the United States. Despite this, we identified 29 kidney biopsies of untreated MCD patients, of which
10 had either strongly or weakly positive glomerular staining for activated STAT6. Antibody staining of
formalin-fixed paraffin-embedded tissue can be challenging, and we were careful to score only for strong
nuclear staining in glomerular nuclei. This was clear-cut in two of our samples, as blindly evaluated by
three pathologists independently. In some of the samples (8 of 29 patients, 1 of 22 controls), glomerular
nuclear staining was detected, along with weak cytoplasmic staining in glomerular and/or tubular cells.
While the cytoplasmic staining likely represents nonspecific background staining, we categorized these
samples in a separate group. Importantly, both groups of patients with pSTAT6 staining responded to steroids, consistent with an immune mechanism of disease.
Most of our samples did not show pSTAT6, supporting the heterogeneity of MCD, which may have
other causes (76–78), such as CLCF1 (47) or ANGPTL4 (78). Additionally, while 90% of MCD patients
respond to glucocorticoids (79), most of these patients will experience a relapse requiring additional therapy (79, 80). The identification of a subset of patients with MCD due to IL-4 may lead to more personalized
and specific therapeutic approaches for the treatment of SSNS. Our work also potentially explains the association of atopy with MCD as well as the efficacy of steroids and rituximab in some patients.

Methods
Reagents. Anti-SMPDL3B polyclonal antibody was purchased from Genway (catalog GWB-2281D4).
Anti-HA (catalog 901501, clone 16B12) antibody, Alexa Fluor 488–conjugated anti-HA (catalog 901509,
clone 16B12) antibody, Alexa Fluor 488 IgG1, k isotype control (catalog 400132), and Alexa Fluor 647
mouse IgG2a, k isotype control (catalog 400234) were purchased from Biolegend. Anti-CD20 polyclonal
antibody (catalog PA5-16701) was purchased from Thermo Fisher Scientific. Anti–β-actin antibody (catalog A1978, clone AC-15) was purchased from MilliporeSigma. Rituximab was produced in-house by the
Antibody Engineering Department at Genentech (81). Alexa Fluor 647–conjugated rituximab was generated using the Alexa Fluor 647 Antibody Labeling Kit (Thermo Fisher Scientific). Recombinant murine
IL-13 and TNF-α (Peprotech) and recombinant murine EGF (Cell Signaling Technology) were reconstituted using the manufacturer’s recommendations. Recombinant murine IL-4, IFN-γ, and anti-mouse IL-4
monoclonal antibody (clone 11B11) (82) were gifts from Robert Schreiber, Washington University in St.
Louis. FITC-conjugated anti-HEL monoclonal antibody (clone F10.6.6; Emil Unanue, Washington University School of Medicine) (83) and nephrotoxic serum (Jeffrey Kopp, National Institute of Diabetes and
Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA) were also provided. FITC-conjugated
polyclonal anti-mouse C3 F(ab′)2 fragment (catalog 0855510) was purchased from MP Biomedicals. AntipSTAT6 (pTyr641, catalog SAB4300038) polyclonal antibody was purchased from MilliporeSigma. All
secondary antibodies used purchased from Jackson ImmunoResearch Laboratories Inc.
Mice. Mice were maintained under specific pathogen–free conditions in the Washington University
School of Medicine animal facilities according to institutional animal care guidelines. 129X1/SvJ (catalog
000691), B6.129S2-Ighmtm1Cgn/J (muMT) (84) (catalog 0002288), and B6.129P2-IL4tm1Cgn/J (IL-4–deficient)
(85) (catalog 0002253) mice were purchased from Jackson Laboratory. HELmuMT (MD4 line) mice (86)
(originally purchased from Jackson Laboratory, catalog 002595) were provided by Emil Unanue. IL-4–deficient HELmuMT mice were generated in two steps: (a) crossing IL-4–knockout mice to muMT mice to
produce B cell–deficient, IL-4–deficient mice, and (b) crossing IL-4–deficient, muMT mice with HELmuMT
to produce IL-4–deficient mice with HEL-transgenic B cells. All mice used were 6- to 8-week-old females.
Generation of HA-tagged SMPDL3B construct. A mammalian expression construct of human SMPDL3B
(pCMV6-XL5 human SMPDL3B transcript variant 1, NM_014474) was purchased from Origene. HA-tag
(YPYDVPDYA) was inserted downstream of the signal peptide (aa 1–18) using the QuikChange II XL
site-directed mutagenesis kit (Agilent) according to the manufacturer’s instructions.
Cell culture and transient transfection. 293T cells (catalog CRL-3216, ATCC) and HeLa cells (catalog
CCL-2, ATCC) were maintained at 37°C in DMEM supplemented with 10% FBS. 293T cells and HeLa
cells were transfected using Lipofectamine 2000 and Lipofectamine 3000 (ThermoFisher), respectively, in
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6-well plates at approximately 70% confluency. Conditionally immortalized murine podocyte cell line generation and propagation have been previously described (87, 88). Podocytes were propagated at 33˚C (permissive temperature) on collagen-I–coated dishes in RPMI, 10% FBS, and 10 U/ml recombinant mouse
IFN-γ. Differentiation was induced by changing media to RPMI, 5% FBS without IFN-γ, and shifting
the cells to 37°C (nonpermissive temperature) for at least 7 days. After differentiation, cells arrested their
growth, increased size, and developed elongated cell processes.
Western blot. Cells were lysed in a modified RIPA lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 5
mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, cOmplete mini protease inhibitor cocktail [Roche])
for 30 minutes on ice. Samples were separated by SDS-PAGE, transferred to nitrocellulose membranes, and
immunoblotted for SMPDL3B, HA, CD20, and β-actin. The blots were visualized by infrared imaging on
an Odyssey Imaging System (LI-COR Biosciences). To remove glycan groups, samples were treated with
PNGase F (New England Biolabs) according to the manufacturer’s instructions prior to SDS-PAGE.
Flow cytometry. The cells were washed with ice-cold PBS and dissociated using a nonenzymatic cell
dissociation buffer (Thermo Fisher Scientific). For nonfixed cells, cells were directly resuspended in FACS
buffer (2% FBS and 2 mM EDTA in 1× PBS). For fixed cells, cells were incubated in 4% PFA (Electron
Microscopy Sciences) in PBS (pH 7.4) for 15 minutes at room temperature, washed 3 times in cold PBS,
and then resuspended in FACS buffer. Cells were incubated with Alexa Fluor 488–conjugated anti-HA
antibody (0.5 μg/ml) and Alexa Fluor 647–conjugated rituximab (5 μg/ml) for 30 minutes at 4°C. FACS
data were collected on a BD LSRFortessa flow cytometer (BD Biosciences) and analyzed with FlowJo
software (FlowJo).
Light and immunofluorescence microscopy. To confirm membrane localization of HA-SMPDL3B, 293T
cells were plated and transfected in Nunc Lab-Tek II CC2 chamber slides (Thermo Fisher Scientific). Cells
were fixed with 4% PFA in PBS for 15 minutes at room temperature, washed, and stained with Alexa Fluor
488–conjugated anti-HA antibody (0.5 μg/ml) overnight at 4°C. Coverslips were mounted with ProLong
Gold Antifade Mountant with DAPI (Thermo Fisher Scientific), and images were captured with a Nikon
A1R confocal microscope. For H&E staining, kidneys were fixed with 10% buffered formalin solution
and embedded in paraffin. 5-μm sections were collected and then stained with H&E. Otherwise, kidneys
were snap frozen in OCT media and 7-μm sections were collected. For immunofluorescence, sections
were stained with primary antibody for 1 hour at room temperature (anti-HEL = 1:250, anti-Ig = 1:200,
anti-C3 = 1:200) and treated with the appropriate secondary antibody. Some sections were counterstained
with Hoechst dye to visualize nuclei. Coverslips were mounted with ProLong Antifade mounting medium
(Invitrogen), and images were captured with an Olympus FluoView FV1000 microscope. For immunohistochemistry, mice were anesthetized and then perfused with 4% PFA. Kidneys were cryoprotected with
sucrose solution. Deidentified sections from human kidney biopsies were obtained from the Kidney Translational Research Core at Washington University in St. Louis, the University of Michigan, and Guy’s & St.
Thomas’ Hospital (London, United Kingdom). The diagnosis of MCD was confirmed by the absence of
light and immunofluorescence pathology and the presence of diffuse foot process effacement by transmission electron microscopy. Control patients included those with the following diagnoses: tubulointerstitial
nephritis, acute kidney injury in the absence of glomerular pathology, clean margins from kidneys resected for renal cell carcinoma, and transplanted donor kidney at the time of transplant into recipient (off
of immunosuppression). Formalin-fixed paraffin-embedded human kidney biopsy sections were subject
to tris-EDTA antigen retrieval prior to immunostaining. Frozen sections were fixed in 4% PFA. Kidney
sections were stained with primary antibody (anti-pSTAT6 = 1:100) overnight at +4°C, followed by incubation with secondary antibody. Sections were developed using the DAB Substrate Kit (Thermo Scientific).
Counterstaining was performed with hematoxylin and 10 mM sodium bicarbonate solution. Sections were
dehydrated and mounted with VectaMount (Vector Laboratories). Images were obtained using a Nikon
Eclipse E800 microscope.
Membrane ruffling assay and kymograph analysis. Murine podocytes were cultured in glass-bottomed
dishes at 37˚C for 10 days to allow for full differentiation. Eight hours prior to imaging, the cells
were washed and cultured in serum-free media to arrest any baseline membrane ruffling. Sequential
images were captured by an Olympus FluoView FV1000 microscope every 10 seconds for a 20-minute
duration prior to and after cytokine addition. Anti–IL-4 antibody and JAK inhibitor were added to
podocytes 1 hour prior to IL-4 addition. Olympus Fluoview software was used to assemble movies.
The ImageJ plug-in, Multiple Kymograph (NIH; http://rsbweb.nih.gov/ij), was used to create kymoinsight.jci.org   https://doi.org/10.1172/jci.insight.81836
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graphs at 5 different locations of maximum membrane ruffling for each cell imaged (89). Ten actin
spikes were measured for each kymograph, and average length (ruffling index) was determined as
previously described (27).
Scanning electron microscopy. For visualizing foot processes in minced renal cortices, kidneys were
harvested from 129X1/SvJ mice and placed in media composed of RPMI/F12, 15 mM HEPES, 10
pM PGE1 (MilliporeSigma), 5 μg/ml transferrin (MilliporeSigma), and 10 nM sodium selenate (MilliporeSigma). The cortex of the kidney was minced using sterile blades and cultured in media with or
without cytokine or antibody for 20 minutes at 37°C. The tissue was washed in PBS and then fixed in
0.2 M sodium cacodylate buffer (Electron Microscopy Services) with 2% PFA and 2% glutaraldehyde.
Samples were post-fixed in 1% phosphate-buffered osmium tetroxide, dehydrated in graded ethanols,
and critical-point dried in carbon dioxide. The samples were mounted onto stubs and then sputter-coated using gold/palladium. For all other scanning electron microscopy images, kidneys were harvested
and cortices were diced and processed as described above. Fifteen glomeruli per sample were analyzed
using a Hitachi S-2600H scanning electron microscope at the Microscopy and Digital Imaging Core at
Washington University in St. Louis.
Assessment of pSTAT6 staining. The stratification of pSTAT6 staining (negative, weakly positive, and
strongly positive) was based on these criteria: negative — no nuclear staining or no enhanced nuclear staining over background (cytoplasmic); weakly positive — enhanced nuclear staining noticeable over background; and strongly positive — pronounced nuclear staining over background. Two blinded pathologists
scored all slides for the presence of pSTAT6 staining.
Intravital 2-photon microscopy. The preparation of kidney intravital 2-photon microscopy was adapted from previously described approaches (90–92). Briefly, 8- to 10-week-old mice previously given multimerized HEL were anesthetized with isofluorane and a small vertical incision was made in the flank
of the mouse. The kidney was exposed, and an upper chamber plate painted with a thin ring of VetBond
tissue adhesive (3M) was gently lowered on to the kidney to secure it to the cover glass and seal the
peritoneal cavity. A dual-channel heating system (Warner Instruments) warmed the imaging chamber
to 37°C. CFSE-labeled HEL-specific B cells were then transferred by tail vein injection, followed with
2,000 kD Rhodamine dextran to label vessels and glomeruli. Time-lapse imaging was performed using a
custom-built 2-photon microscope and ImageWarp acquisition software (A&B Software). Images were
acquired either at video rate (30 f/sec) or by time-lapse imaging, where we averaged 15 video-rate
frames (0.5 s/slice) creating a Z-stack of 31 sequential Z-steps (2.5 μm each). Each optical section was
approximately 220 × 240 μm in the x and y dimensions.
IL-4 piggyBac plasmid construction, hydrodynamic injection, and tofacitinib administration. Plasmid encoding murine IL-4 was a gift from Ken Murphy (Washington University in St. Louis). IL-4 was amplified
and cloned into the PB530A-2 vector (System Biosciences) using BamHI and NotI. The piggyBac/IL-4
and transposase vectors were prepped using the Qiagen EndoFree Plasmid Maxi Kit and combined at
a 5:1 ratio (total DNA = 45 μg) in approximately 2 ml TransIT QR Hydrodynamic Delivery Solution
(Mirus Bio). Hydrodynamic injection of these vectors occurred through the tail vein using a 30-gauge
needle. Serum IL-4 was determined using the Mouse IL-4 Quantikine ELISA Kit (R&D Systems). For the
JAK inhibitor experiments, tofacitinib (Selleckchem) was mixed with 0.5% methylcellulose and 0.025%
Tween-20 in water, and 50 mg/kg was administered by oral gavage to mice twice daily.
Assessment of proteinuria. For SDS-PAGE analysis, 5 μl urine was loaded with ×4 Laemmli sample buffer onto a 4%–20% SDS polyacrylamide gel (Bio-Rad). Proteins were visualized by staining the gel with
Coomassie blue. For quantification, the Mouse Albumin ELISA Quantification Set (Bethyl Laboratories
Inc.) and QuantiChrom Creatinine Assay Kit (Bioassay Systems) were used using manufacturer’s directions.
Production of multimerized HEL and injection into mice. HEL (Amresco) was dissolved in sterile PBS
(Hyclone) and treated with NHS-biotin (Thermo Scientific), followed with dialysis using Slide-A-Lyzer
Dialysis Cassettes G2 (Thermo Scientific) against sterile PBS. Avidin (Invitrogen) was slowly added to
the solution of biotinylated HEL to generate multimerized HEL. The size of multimerized HEL was confirmed using SDS-PAGE, followed by Coomassie blue staining. Multimerized HEL (1 mg) was delivered
i.v. via tail vein injection into mice, and organs were harvested 30 minutes to 7 days after infusion.
HEL-specific B cell isolation, polarization, CFSE labeling, and adoptive transfer into mice. Spleens from
HELmuMT or IL-4–deficient HELmuMT mice were collected into a cell strainer (100-μm nylon mesh)
and mashed through. Splenocytes were washed and resuspended in PBS supplemented with 2% FBS
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and 2 mM EDTA. B cells were enriched by negative isolation using the Dynabeads Mouse CD43
(Untouched B cells) Isolation Kit (Invitrogen). B cell purity was validated by flow cytometry (using
B220 as the B cell marker), and consistently was >95%. Unpolarized B cells were polarized into IL-4–
secreting B cells as previously described (13, 36). Purified HEL-specific B cells were CFSE-labeled per
the manufacturer’s instructions (CellTrace CFSE Cell Proliferation Kit, Molecular Probes/Invitrogen).
5 × 106 B cells were transferred via tail vein injection into wild-type hosts previously administered multimerized HEL.
Statistics. All data, except for pSTAT6 characterization data, are represented as mean ± SD. For membrane ruffling results, group differences were assessed by repeated-measures 1-way ANOVA with Bonferroni correction. For pSTAT6 characterization, Fisher’s exact test was used. For all other results, 2-tailed
Mann-Whitney test was used. A P value of less than 0.05 was considered significant.
Study approval. All animal experiments were conducted with approval from the Washington University
in St. Louis Animal Care and Use Committee (St. Louis, Missouri, USA). Patient samples were obtained
in a deidentified manner, with institutional review board approval from King’s College/Evelina Children’s
Hospital, the Kidney Translational Research Core (Washington University in St. Louis), and the University
of Michigan.
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